Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Banner Left
Banner Right

US allows ‘morning-after’ pill for 17-year-olds

US allows ‘morning-after’ pill for 17-year-olds

WASHINGTON – Women’s groups cheered the government’s decision to allow 17-year-olds to buy the ‘morning-after’ emergency contraceptive without a doctor’s prescription, but conservatives denounced it as a blow to parental supervision of teens.

The Food and Drug Administration said on Wednesday it would accept, not appeal, a federal judge’s order that lifts Bush administration restrictions limiting over-the-counter sales of ‘Plan B’ to women 18 and older. US District Judge Edward Korman ruled last month in a lawsuit filed in New York that President George W. Bush’s appointees let politics, not science, drive their decision to restrict over-the-counter access.
Women’s groups said the FDA’s action was long overdue, since the agency’s own medical reviewers had initially recommended that the contraceptive be made available without any age restrictions.
Korman ordered the FDA to let 17-year-olds get the birth control pills. He also directed the agency to evaluate clinical data to determine whether all age restrictions should be lifted.
The FDA’s latest action does not mean that Plan B will be immediately available to 17-year-olds. The manufacturer must first submit a request.
‘It’s a good indication that the agency will move expeditiously to ensure its policy on Plan B is based solely on science,’ said Nancy Northup, president of the Center for Reproductive Rights, which filed the lawsuit.
‘Parents should be furious at the FDA’s complete disregard of parental rights and the safety of minors,’ said Wendy Wright, president of Concerned Women for America.
Plan B is emergency contraception that contains a high dose of birth control drugs and will not interfere with an established pregnancy. It works by preventing ovulation or fertilisation. In medical terms, pregnancy begins when a fertilised egg attaches itself to the wall of the uterus.
If taken within 72 hours of unprotected sex, it can reduce a woman’s chances of pregnancy by as much as 89 per cent.
Critics of the contraceptive say Plan B is the equivalent of an abortion pill because it can prevent a fertilised egg from attaching to the uterus. Recent research suggests that’s possible but not likely.
The battle over access to Plan B has dragged on for the better part of a decade, through the terms of three FDA commissioners.
The treatment consists of two pills and sells for $35 to $60. Women must ask for Plan B at the pharmacy counter and show identification with their date of birth.
– Nampa-AP

Stay informed with The Namibian – your source for credible journalism. Get in-depth reporting and opinions for only N$85 a month. Invest in journalism, invest in democracy –
Subscribe Now!

Latest News